By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Ratings late on Tuesday affirmed several ratings of BBB+ for Agilent Technologies.

The BBB+ ratings, which translate to good credit quality, were affirmed for Agilent's Issuer Default Rating, senior unsecured revolving credit facility, and senior unsecured notes. Fitch's actions affect about $2.6 billion of debt, including an undrawn $400 million revolving credit facility that expires in 2016, Fitch said.

It rated Agilent's outlook Stable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.